Q-omics provides the consensus-scored KMT2C profile across patient tissues and cancer cell-line models. KMT2C expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, KMT2C is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, KMT2C RNA expression shows 21,876 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, THCA, and UVM as cancer lineages where KMT2C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KMT2C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KMT2C survival associations across molecular data types. KMT2C RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KMT2C RNA expression–survival associations across cancer types. High KMT2C expression shows unfavorable associations in CESC, but favorable associations in HNSC, KIRC, LUAD, SCLC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for KMT2C RNA expression.
This table summarizes KMT2C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KMT2C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KMT2C shows lower tumor expression in THCA and higher tumor expression in CHOL, LIHC and KIRP. The THCA box plot shows higher KMT2C RNA expression in normal versus tumor tissue (log2 FC = −0.513, t-test p < 0.001).
This table shows molecular features associated with KMT2C in patient tissues and cancer cell lines. In patient samples, KMT2C shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KMT2C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
